A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
type: MedicalStudy
description: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE3
start date: 2015-10-20
end date: 2025-02-25
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT02421939
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Astellas Pharma Global Development, Inc.
study subject: Leukemia, Acute Myeloid (AML)
keywords: PHASE3
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Leukemia, Acute Myeloid (AML)

AI Analytics
type: Organization